Comparing the current results to its competitors, Ultragenyx Pharmaceutical Inc reported Revenue decrease in the 1 quarter 2026 year on year by -2.36 %, despite the revenue increase by the most of its competitors of 4.87 %, recorded in the same quarter.
Ultragenyx Pharmaceutical Inc , despite income growth by most of its competitors recorded a net loss, despite income increase by most of its competitors of 4990.79 %
June 11, 2024
Ultragenyx Pharmaceutical Inc. recently released compelling data from the Phase 2/3 Orbit study, highlighting the sustained reductions in fracture rates observed in patients with osteogenesis imperfecta (OI) following treatment with setrusumab (UX143). These findings bring hope to individuals facing the challenges associated with OI, a rare genetic disorder characterized by brittle bones and increased susceptibility to fractures.Facts from the Phase 2/3 Orbit Study:The 14-month data from the Phase 2/3 Orbit study revealed that treatment with setrusumab showcased a remarkable 67% reduction in the annualized fracture rate. Furthermore, the median annualized fracture rate for patients on setrusumab remained at ...
May 30, 2024
Advancements in medical research and technology continue to revolutionize treatment options for rare genetic disorders. Recent breakthroughs in gene therapy have demonstrated promising results in addressing the complex challenges associated with diseases such as Glycogen Storage Disease Type Ia (GSDIa), Angelman Syndrome, and Sanfilippo Syndrome Type A (MPS IIIA). This article aims to provide an overview of the significant scientific findings presented by Ultragenyx, a leading biopharmaceutical company, regarding their gene therapy products, DTX401, GTX-102, and UX111.Ultragenyx s Phase 3 study of DTX401 for GSDIa yielded positive top-line results. The treatment showcased a statistically significant reducti...
February 6, 2024
:Sanfilippo Syndrome Type A, also known as Mucopolysaccharidosis type IIIA (MPS IIIA), is a rare genetic disorder characterized by the accumulation of heparan sulfate within the body, leading to severe neurological impairment and cognitive decline. Ultragenyx, a biopharmaceutical company, has recently introduced UX111, a potential groundbreaking treatment for MPS IIIA patients. This article aims to analyze the latest data from the pivotal Transpher A clinical trial and long-term follow-up studies, which demonstrate the significant reduction of heparan sulfate in cerebrospinal fluid through treatment with UX111. Furthermore, the article highlights the correlation between these improvements in heparan sulfate ...
January 3, 2024
:Ultragenyx Pharmaceutical Inc. recently announced the completion of enrollment in its global Phase 1/2 trial of GTX-102 for the treatment of Angelman Syndrome in pediatric patients. This crucial development elucidates a significant stride towards finding a transformative therapeutic intervention for Angelman Syndrome, a neuro-genetic disorder with profound implications for affected children and their families. Preliminary data from the trial, involving at least 20 pediatric patients, is eagerly anticipated in the first half of 2024. This manuscript delves into the particulars of this clinical trial and contextualizes its potential implications within the broader landscape of Angelman Syndrome treatment stra...
Medicure Inc operates as a pharmaceutical company with a business model that focuses on the research, development, and commercialization of innovative cardiovascular and other specialty pharmaceuticals. They aim to address unmet medical needs, improve patient outcomes, and deliver value to healthcare providers and consumers.
MeiraGTx Holdings Plc is a biotechnology company focused on developing gene therapies for inherited and acquired diseases. They leverage their proprietary technology to develop and commercialize innovative treatments that address unmet medical needs.
Larimar Therapeutics Inc's business model revolves around the development and commercialization of innovative therapeutics for the treatment of rare and serious genetic diseases.
Lipocine Inc is a pharmaceutical company focused on developing oral drug delivery systems for hormone therapeutics. Their business model involves conducting research and development to create innovative products that address unmet medical needs in areas such as testosterone replacement therapy and hypogonadism. The company aims to commercialize these proprietary drug candidates and collaborate with industry partners to enhance their potential reach and impact.
Sources:
Ultragenyx Pharmaceutical Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Ultragenyx Pharmaceutical Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
